Trial Profile
Long-Acting, Self-Administered HIV Therapy with the CCR5 Antibody PRO 140 ("NIAID Study")
Status:
Suspended
Phase of Trial:
Phase II
Latest Information Update: 07 Apr 2022
Price :
$35
*
At a glance
- Drugs Leronlimab (Primary)
- Indications HIV infections
- Focus Therapeutic Use
- Acronyms NIAID
- 30 Mar 2022 Status changed from planning to suspended, according to a CytoDyn media release
- 30 Mar 2022 According to a CytoDyn media release, the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on Leronlimab HIV program.The partial clinical hold on the HIV program impacts patients currently enrolled in extension trials. These patients will be transitioned to other available therapeutics and no clinical studies can be initiated or resumed until the partial clinical hold is resolved.
- 29 Apr 2013 After a 3-year delay, an agreement has been reached with Ajinomoto Althea, a fill and finish plan has been put in place, and enrolment is expected to start in the fourth quarter of 2013, according to a CytoDyn media release.